NDAORALTABLET, EXTENDED RELEASE1 Generic Approved
Approved
Jan 1959
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 1w ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MESTINON (pyridostigmine bromide) is an anticholinesterase agent that inhibits acetylcholinesterase to facilitate neuromuscular transmission. It is used primarily to treat myasthenia gravis and to reverse neuromuscular blockade induced by nondepolarizing muscle relaxants during anesthesia. The drug has a longer duration of action and lower incidence of muscarinic side effects compared to neostigmine.
LOE Approaching
With LOE approaching, the brand team is likely in defense-and-efficiency mode; expect smaller team size and focus on market retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Testing Mestinon and Exercise in Fibromyalgia
Started Sep 2002
178 enrolled
Fibromyalgia
Career Relevance
Working on MESTINON offers exposure to orphan/niche market dynamics and lifecycle defense strategy rather than growth-stage innovation. This role is better suited to professionals interested in established product stewardship, market access in specialized indications, or preparing for generic transition management.
Brand Manager
Worked on MESTINON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.